BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 14, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Neurology/psychiatric

TREM2 agonists disclosed in Roche patent

Jan. 21, 2025
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease, frontotemporal dementia, multiple sclerosis, Nasu-Hakola disease, Parkinson’s disease, rheumatoid arthritis and stroke.
Read More
Neurology/psychiatric

Northeastern University patents new cannabinoid CB1 receptor inhibitors and MAGL inhibitors

Jan. 21, 2025
Northeastern University has disclosed cannabinoid CB1 receptor allosteric modulators and monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of pain, inflammation, anxiety, psychosis, traumatic brain injury, post-traumatic stress disorder, epilepsy and neurodegenerative diseases.
Read More
Ocular

Gemvax & Kael describes new peptides for AMD, cerebral amyloid angiopathy and Alzheimer’s

Jan. 21, 2025
Gemvax & Kael Co. Ltd. has identified peptides reported to be useful for the treatment of age-related macular degeneration (AMD), cerebral amyloid angiopathy and Alzheimer’s disease.
Read More
3D illustration of acute myeloid leukemia cells
Immuno-oncology

5T4 as a target for CAR T therapies against acute myeloid leukemia

Jan. 21, 2025
Researchers from Oxford Biomedica (UK) Ltd. have published findings from their work aiming to identify antigens that could represent novel targets for CAR T-cell therapies against acute myeloid leukemia (AML).
Read More
Cancer

Combination of TB-01 and TAS-102 enhances colorectal cancer treatment in preclinical model

Jan. 21, 2025
Colorectal cancer remains the third most common malignancy worldwide, with advanced stages presenting significant challenges for treatment. A recently published study highlights the potential of combining the antiangiogenic peptide TB-01 (PEP-06), a drug in phase II studies in China, with the approved cytotoxic drug trifluridine/tipiracil (TAS-102) as a treatment for colorectal cancer.
Read More
Neurology/psychiatric

SIX1 blockade ameliorates spinal cord injury damage in mice

Jan. 21, 2025
Spinal cord injury (SCI) is characterized by the temporary or permanent loss of motion or sensation function caused by damage to the spinal cord. Among the mechanisms behind SCI, neuroinflammation is crucial as it modulates the sequelae of SCI, where microglia play a critical role, with M1 macrophages being the pro-inflammatory ones and M2 the anti-inflammatory phenotype.
Read More
Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

NI-3201, an example of effective PD-L1-dependent CD28 costimulation

Jan. 21, 2025
Cancer immunotherapy has represented a significant advancement in cancer treatment; however, many patients experience relapse or develop resistance to this treatment. Bispecific antibodies that selectively engage T-cell costimulatory molecules have emerged as a novel therapeutic strategy to overcome the limitations of immunotherapy.
Read More
DNA in test tubes
Drug design, drug delivery & technologies

Circio partners with 4basbio on synthetic Circvec DNA vectors

Jan. 21, 2025
Circio Holding ASA has entered a partnership with 4basebio plc for joint development and in vivo delivery testing of synthetic Circvec DNA vectors.
Read More
Lungs wireframe illustration
Infection

Glox awarded funding to advance antibiotics for antimicrobial-resistant lung infections in cystic fibrosis

Jan. 21, 2025
Glox Therapeutics Ltd. has been awarded a share of a £3 million (US$3.7 million) collaborative discovery program launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) syndicate. The syndicate is a cross-sector initiative driven by Medicines Discovery Catapult, Lifearc and Cystic Fibrosis Trust.
Read More
Steadying hand while reaching for glass
Neurology/psychiatric

Dual-action compound shows promise for Parkinson’s motor and nonmotor symptoms

Jan. 21, 2025
Parkinson’s disease, characterized by progressive dopamine neuron loss, leads to motor deficits such as bradykinesia and rigidity, as well as nonmotor symptoms like cognitive decline and depression. While L-DOPA alleviates motor symptoms, long-term use often results in side effects, including motor fluctuations and dyskinesias, as well as nonmotor (psychotic-like) side effects.
Read More
Previous 1 2 … 324 325 326 327 328 329 330 331 332 … 17931 17932 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 12, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Illustration of head with maze that is missing parts

    CTAD 2025: The challenges of combination therapies for dementia

    BioWorld Science
    At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing